Without cheating (i.e., looking at Solvay's books) I would guess the answer is that a large chunk of the purchased assets will go on the books as acquired R&D.
That’s almost right, but not quite.
Hint: the most important acquired asset in the ABT-Solvay deal is an asset of omission.